文献速递神经肿瘤

靶向转录延伸治疗弥漫性内生性脑桥胶质瘤

Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
PubMed 文献 · Neuro Oncol · 2021-01-01

本研究探讨通过破坏超延伸复合物(SEC)来治疗H3K27M突变型弥漫性内生性脑桥胶质瘤(DIPG)。抑制SEC核心组分AFF4可降低DIPG细胞生长;化合物KL-1破坏SEC功能后,全基因组RNA聚合酶II占据增加,抑制促增殖与分化相关转录,在体外抑制DIPG细胞生长并增加凋亡,在PDX小鼠中延长生存。

要点

  • 抑制SEC核心组分AFF4可显著降低H3K27M突变型DIPG细胞生长。
  • KL-1破坏SEC功能,增加全基因组Pol II占据并抑制促增殖转录。
  • KL-1在体外抑制DIPG细胞生长、增加凋亡,在PDX小鼠中延长生存。

核心结论

  • 通过KL-1破坏SEC在体外和体内均增加治疗获益,支持KL-1在H3K27M突变型DIPG中具有潜在治疗活性。

研究设计与样本

  • 研究使用shRNA抑制H3K27M突变型DIPG细胞中SEC核心组分AFF4的表达。
  • 使用肽模拟先导化合物KL-1破坏SEC功能组分,并通过细胞活力、集落形成和凋亡实验分析其效应。
  • 采用RNA测序和ChIP测序确定KL-1对基因表达和染色质占据的影响。
  • 对携带H3K27M突变型DIPG患者来源异种移植瘤(PDX)的小鼠给予KL-1治疗,通过生物发光成像监测颅内肿瘤生长,以动物生存评估治疗反应。

主要发现

  • 敲低AFF4显著降低H3K27M突变型DIPG细胞的生长。
  • KL-1增加全基因组RNA聚合酶II(Pol II)占据,并抑制涉及多个促进DIPG细胞增殖和分化的细胞过程的转录。
  • KL-1治疗抑制DIPG细胞生长、增加凋亡,并延长携带H3K27M突变型DIPG PDX动物的生存。

临床怎么用

  • KL-1通过破坏SEC抑制H3K27M突变型DIPG生长并延长PDX小鼠生存,提示靶向转录延伸可能成为该亚型DIPG的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is associated with transcriptional dysregulation driven by H3K27 mutation. The super elongation complex (SEC) is required for transcriptional elongation through release of RNA polymerase II (Pol II). Inhibition of transcription elongation by SEC disruption can be an effective therapeutic strategy of H3K27M-mutant DIPG. Here, we tested the effect of pharmacological disruption of the SEC in H3K27M-mutant DIPG to advance understanding of the molecular mechanism and as a new therapeutic strategy for DIPG. METHODS: Short hairpin RNAs (shRNAs) were used to suppress the expression of AF4/FMR2 4 (AFF4), a central SEC component, in H3K27M-mutant DIPG cells. A peptidomimetic lead compound KL-1 was used to disrupt a functional component of SEC. Cell viability assay, colony formation assay, and apoptosis assay were utilized to analyze the effects of KL-1 treatment. RNA- and ChIP-sequencing were used to determine the effects of KL-1 on gene expression and chromatin occupancy. We treated mice bearing H3K27M-mutant DIPG patient-derived xenografts (PDXs) with KL-1. Intracranial tumor growth was monitored by bioluminescence image and therapeutic response was evaluated by animal survival. RESULTS: Depletion of AFF4 significantly reduced the cell growth of H3K27M-mutant DIPG. KL-1 increased genome-wide Pol II occupancy and suppressed transcription involving multiple cellular processes that promote cell proliferation and differentiation of DIPG. KL-1 treatment suppressed DIPG cell growth, increased apoptosis, and prolonged animal survival with H3K27M-mutant DIPG PDXs. CONCLUSIONS: SEC disruption by KL-1 increased therapeutic benefit in vitro and in vivo, supporting a potential therapeutic activity of KL-1 in H3K27M-mutant DIPG.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Katagi H, Takata N, Aoi Y, et al. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma. Neuro Oncol. 2021. PMID: 33471107. doi:10.1093/neuonc/noab009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。